On 3 June, Organon, a new business spun out of Merck & Co. comprising biosimilars, women’s health and established products, is poised to begin trading as a new independent company. (Also see "Organon Is Ready To Launch And Makes The Case To Investors" - Scrip, 3 May, 2021.)
Set to generate $6.1bn-$6.4bn in 2021 annual revenues on a pro forma basis, Organon will be overseen by a groundbreaking...